{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:26:31Z","timestamp":1709771191998},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00120-024-02283-w","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T14:03:04Z","timestamp":1707400984000},"page":"234-240","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage-Lymphadenektomie beim Prostatakarzinom","Salvage lymphadenectomy for recurrent prostate cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"Thomas","family":"Horn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flemming","family":"Lischewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"issue":"10231","key":"2283_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS, Lawrentschuk\u00a0N, Francis\u00a0RJ, Tang\u00a0C, Vela\u00a0I, Thomas\u00a0P et\u00a0al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a\u00a0prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216","journal-title":"Lancet"},{"key":"2283_CR2","volume-title":"Edn. presented at the EAU annual congress milan","author":"EAU Guidelines","year":"2023","unstructured":"Guidelines\u00a0EAU (2023) Edn. presented at the EAU annual congress milan"},{"issue":"1","key":"2283_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/JU.0000000000003518","volume":"210","author":"LBA02-09 EMBARK","year":"2023","unstructured":"LBA02-09 EMBARK (2023) A\u00a0phase\u00a03 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. J\u00a0Urol 210(1):224\u2013226","journal-title":"J Urol"},{"issue":"5","key":"2283_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips\u00a0R, Shi\u00a0WY, Deek\u00a0M, Radwan\u00a0N, Lim\u00a0SJ, Antonarakis\u00a0ES et\u00a0al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase\u00a02 randomized clinical trial. JAMA Oncol 6(5):650\u2013659","journal-title":"JAMA Oncol"},{"issue":"5","key":"2283_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost\u00a0P, Reynders\u00a0D, Decaestecker\u00a0K, Fonteyne\u00a0V, Lumen\u00a0N, De Bruycker\u00a0A et\u00a0al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a\u00a0prospective, randomized, multicenter phase\u00a0II trial. J\u00a0Clin Oncol 36(5):446\u2013453","journal-title":"J Clin Oncol"},{"key":"2283_CR6","doi-asserted-by":"crossref","unstructured":"Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E et\u00a0al (2023) The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a\u00a0systematic review and meta-analysis of prospective studies. Eur Urol","DOI":"10.1016\/j.eururo.2023.10.012"},{"issue":"29","key":"2283_CR7","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek\u00a0MP, Van der Eecken\u00a0K, Sutera\u00a0P, Deek\u00a0RA, Fonteyne\u00a0V, Mendes\u00a0AA et\u00a0al (2022) Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J\u00a0Clin Oncol 40(29):3377\u20133382","journal-title":"J Clin Oncol"},{"issue":"6","key":"2283_CR8","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.7150\/thno.18421","volume":"7","author":"CA Jilg","year":"2017","unstructured":"Jilg\u00a0CA, Drendel\u00a0V, Rischke\u00a0HC, Beck\u00a0T, Vach\u00a0W, Schaal\u00a0K et\u00a0al (2017) Diagnostic accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET\/CT before salvage lymph node dissection for recurrent prostate cancer. Theranostics 7(6):1770\u20131780","journal-title":"Theranostics"},{"issue":"12","key":"2283_CR9","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2967\/jnumed.120.260091","volume":"62","author":"I Rauscher","year":"2021","unstructured":"Rauscher\u00a0I, Karimzadeh\u00a0A, Schiller\u00a0K, Horn\u00a0T, D\u2019Alessandria\u00a0C, Franz\u00a0C et\u00a0al (2021) Detection efficacy of (18)F-rhPSMA\u20117.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J\u00a0Nucl Med 62(12):1719\u20131726","journal-title":"J Nucl Med"},{"issue":"9","key":"2283_CR10","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00259-019-04385-6","volume":"46","author":"M Wondergem","year":"2019","unstructured":"Wondergem\u00a0M, Jansen\u00a0BHE, van der Zant\u00a0FM, van der Sluis\u00a0TM, Knol\u00a0RJJ, van Kalmthout\u00a0LWM et\u00a0al (2019) Early lesion detection with (18)F-DCFPyL PET\/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 46(9):1911\u20131918","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2283_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera\u00a0M, Papa\u00a0N, Roberts\u00a0M, Williams\u00a0M, Udovicich\u00a0C, Vela\u00a0I et\u00a0al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a\u00a0systematic review and meta-analysis. Eur Urol 77(4):403\u2013417","journal-title":"Eur Urol"},{"issue":"1","key":"2283_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","volume":"83","author":"S Knipper","year":"2023","unstructured":"Knipper\u00a0S, Irai\u00a0MM, Simon\u00a0R, Koehler\u00a0D, Rauscher\u00a0I, Eiber\u00a0M et\u00a0al (2023) Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery. Eur Urol 83(1):62\u201369","journal-title":"Eur Urol"},{"issue":"4","key":"2283_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.eururo.2019.03.045","volume":"76","author":"T Horn","year":"2019","unstructured":"Horn\u00a0T, Kr\u00f6nke\u00a0M, Rauscher\u00a0I, Haller\u00a0B, Robu\u00a0S, Wester\u00a0HJ et\u00a0al (2019) Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a\u00a0favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. Eur Urol 76(4):517\u2013523","journal-title":"Eur Urol"},{"issue":"1","key":"2283_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/JU.0000000000001697","volume":"206","author":"J Linxweiler","year":"2021","unstructured":"Linxweiler\u00a0J, Sprenk\u00a0J, Cascetta\u00a0K, Pryalukhin\u00a0A, H\u00f6lters\u00a0S, Zeuschner\u00a0P et\u00a0al (2021) Robotic salvage lymph node dissection in recurrent prostate cancer: lessons learned from 68 cases and implications for future clinical management. J\u00a0Urol 206(1):88\u201396","journal-title":"J Urol"},{"issue":"4","key":"2283_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","volume":"76","author":"G Ploussard","year":"2019","unstructured":"Ploussard\u00a0G, Gandaglia\u00a0G, Borgmann\u00a0H, de Visschere\u00a0P, Heidegger\u00a0I, Kretschmer\u00a0A et\u00a0al (2019) Salvage lymph node dissection for nodal recurrent prostate cancer: a\u00a0systematic review. Eur Urol 76(4):493\u2013504","journal-title":"Eur Urol"},{"issue":"7","key":"2283_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2967\/jnumed.118.220541","volume":"60","author":"CA Jilg","year":"2019","unstructured":"Jilg\u00a0CA, Drendel\u00a0V, Rischke\u00a0HC, Beck\u00a0TI, Reichel\u00a0K, Kr\u00f6nig\u00a0M et\u00a0al (2019) Detection rate of (18)F-choline PET\/CT and (68)Ga-PSMA-HBED-CC PET\/CT for prostate cancer lymph node metastases with direct link from PET to histopathology: dependence on the size of tumor deposits in lymph nodes. J\u00a0Nucl Med 60(7):971\u2013977","journal-title":"J Nucl Med"},{"issue":"6","key":"2283_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.eururo.2020.06.047","volume":"78","author":"CA Bravi","year":"2020","unstructured":"Bravi\u00a0CA, Fossati\u00a0N, Gandaglia\u00a0G, Suardi\u00a0N, Mazzone\u00a0E, Robesti\u00a0D et\u00a0al (2020) Assessing the best surgical template at salvage pelvic lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: when can bilateral dissection be omitted? Results from a\u00a0multi-institutional series. Eur Urol 78(6):779\u2013782","journal-title":"Eur Urol"},{"key":"2283_CR18","doi-asserted-by":"crossref","unstructured":"Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS et\u00a0al (2018) (99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol","DOI":"10.1016\/j.eururo.2018.03.013"},{"issue":"1","key":"2283_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13550-015-0147-6","volume":"5","author":"M Schottelius","year":"2015","unstructured":"Schottelius\u00a0M, Wirtz\u00a0M, Eiber\u00a0M, Maurer\u00a0T, Wester\u00a0HJ (2015) (111)In]PSMA-I&T:\u00a0expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res 5(1):68","journal-title":"EJNMMI Res"},{"issue":"1","key":"2283_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.euf.2018.09.014","volume":"5","author":"S Knipper","year":"2019","unstructured":"Knipper\u00a0S, Tilki\u00a0D, Mansholt\u00a0J, Berliner\u00a0C, Bernreuther\u00a0C, Steuber\u00a0T et\u00a0al (2019) Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a\u00a0comparison between conventional surgical approach and prostate-specific ,membrane antigen-radioguided surgery. Eur Urol Focus 5(1):50\u201353","journal-title":"Eur Urol Focus"},{"issue":"5","key":"2283_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","volume":"78","author":"CA Bravi","year":"2020","unstructured":"Bravi\u00a0CA, Fossati\u00a0N, Gandaglia\u00a0G, Suardi\u00a0N, Mazzone\u00a0E, Robesti\u00a0D et\u00a0al (2020) Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol 78(5):661\u2013669","journal-title":"Eur Urol"},{"issue":"6","key":"2283_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.euf.2018.02.015","volume":"5","author":"T Steuber","year":"2019","unstructured":"Steuber\u00a0T, Jilg\u00a0C, Tennstedt\u00a0P, De Bruycker\u00a0A, Tilki\u00a0D, Decaestecker\u00a0K et\u00a0al (2019) Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a\u00a0multi-institutional case-control study. Eur Urol Focus 5(6):1007\u20131013","journal-title":"Eur Urol Focus"},{"issue":"2","key":"2283_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.eururo.2014.02.011","volume":"67","author":"N Suardi","year":"2015","unstructured":"Suardi\u00a0N, Gandaglia\u00a0G, Gallina\u00a0A, Di Trapani\u00a0E, Scattoni\u00a0V, Vizziello\u00a0D et\u00a0al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a\u00a0single-institution series with a\u00a0minimum follow-up of 5\u00a0years. Eur Urol 67(2):299\u2013309","journal-title":"Eur Urol"},{"issue":"1","key":"2283_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2018.09.009","volume":"75","author":"N Fossati","year":"2019","unstructured":"Fossati\u00a0N, Suardi\u00a0N, Gandaglia\u00a0G, Bravi\u00a0CA, Soligo\u00a0M, Karnes\u00a0RJ et\u00a0al (2019) Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a\u00a0large, multi-institutional analysis. Eur Urol 75(1):176\u2013183","journal-title":"Eur Urol"},{"issue":"4","key":"2283_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00066-014-0763-5","volume":"191","author":"HC Rischke","year":"2015","unstructured":"Rischke\u00a0HC, Schultze-Seemann\u00a0W, Wieser\u00a0G, Kronig\u00a0M, Drendel\u00a0V, Stegmaier\u00a0P et\u00a0al (2015) Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 191(4):310\u2013320","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2283_CR26","first-page":"406","volume":"20","author":"A De Bruycker","year":"2020","unstructured":"De Bruycker\u00a0A, Spiessens\u00a0A, Dirix\u00a0P, Koutsouvelis\u00a0N, Semac\u00a0I, Liefhooghe\u00a0N et\u00a0al (2020) PEACE V\u2014Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a\u00a0study protocol for a\u00a0randomized controlled phase\u00a0II trial. BMC. Cancer 20(1):406","journal-title":"Cancer"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02283-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02283-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02283-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:05:09Z","timestamp":1709737509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02283-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02283-w","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"15 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Horn, F.\u00a0Lischewski und J.E.\u00a0Gschwend geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}